GlassScriptPhysician profile
Paul M Rutkowski
NPI 1003078254
$193,734.22
in general payments reported to CMS, 2019-2025
20 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $64.45 · 2021: $116 · 2022: $35K · 2023: $87K · 2024: $71K · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $157K · Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,875.00 |
| Food and Beverage | $1,345.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $156,875.00 | 2023-2024 | |
| Csl Behring | $34,762.50 | 2022 | |
| Novo Nordisk INC | $436.73 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $426.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Radius Health, INC. | $202.81 | 2023-2025 | Tymlos |
| Medtronic, INC. | $171.23 | 2025 | Symplicity G3 |
| Lilly USA, LLC | $167.86 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.06 | 2021-2025 | Jardiance, Tradjenta |
| Avanir Pharmaceuticals, INC. | $98.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $79.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.43 | 2022-2023 | |
| Abbott Laboratories | $53.70 | 2021-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $52.85 | 2021-2024 | Eliquis |
| Glaxosmithkline, LLC. | $49.64 | 2023-2025 | Trelegy Ellipta |
| Kyowa Kirin, INC. | $46.71 | 2023 | Crysvita |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $38.17 | 2025 | Voquezna |
| Amgen INC. | $29.03 | 2020 | |
| Biotronik Nro, INC. | $28.15 | 2024 | Prospera |
| Exact Sciences Corporation | $21.00 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $13.78 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rutkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.